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Abstract: Inflammation and intestinal permeability are believed to be
paramount features in the development of alcohol-related liver damage.
We aimed to assess the impact of 3 surrogate markers of inflammation
(anemia, fibrinogen, and ferritin levels) on mid-term mortality of
patients with alcohol dependence.
This longitudinal study included patients with alcohol dependence
admitted for hospital detoxification between 2000 and 2010. Mortality
was ascertained from clinical charts and the mortality register. Associ-
ations between markers of inflammation and all-cause mortality were
analyzed with mortality rates and Cox proportional hazards regression
models.
We also performed a subgroup analysis of mortality rates in patients
with anemia, based on their mean corpuscular volume (MCV).
We included 909 consecutive patients with alcohol dependence.
Patients were mostly male (80.3%), had a median age of 44 years
(interquartile range [IQR]: 38–50), and upon admission, their median
alcohol consumption was 192 g/day (IQR: 120–265). At admission, 182
(20.5%) patients had anemia; 210 (25.9%) had fibrinogen levels
>4.5mg/dL; and 365 (49.5%) had ferritin levels >200 ng/mL. At the
end of follow-up (median 3.8 years [IQR: 1.8–6.5], and a total of
3861.07 person-years), 118 patients had died (12.9% of the study
population). Cox regression models showed that the presence of anemia
at baseline was associated with mortality (hazard ratio [HR]: 1.67, 95%
confidence interval [CI]: 1.11–2.52, P< 0.01); no associations were
found between mortality and high fibrinogen or high ferritin levels.
A subgroup of patients with anemia was analyzed and compared to a
control group of patients without anemia and a normal MCV. The
mortality ratios of patients with normocytic and macrocytic anemia
were 3.25 (95% CI: 1.41–7.26; P< 0.01) and 3.39 (95% CI: 1.86–6.43;Paola Zuluaga, Inm s, Jordi Tor,
t Muga
accurate markers of systemic inflammation are needed to serve as
prognostic factors for poor outcomes in this subset of patients.
(Medicine 94(10):e607)
Abbreviations: ALT = alanine amino-transferase, ARLD =
alcohol-related liver disease, AST = aspartate amino-transferase,
AUD = alcohol use disorder, CI = Confidence Interval, CRP = C-
reactive protein, HBcAb = Hepatitis B core antibody, HBsAg =
Hepatitis B surface antigen, HBV = hepatitis B virus, HCV =
hepatitis C virus, HIV = human immunodeficiency virus, HR =
hazard ratio, ICD-10 = International Classification of Diseases,
version 10, IQR = interquartile range, MVC = mean corpuscular
volume, p-y = person-years.
INTRODUCTION
A lcohol consumption is widespread in western countries.
1
Alcohol abuse is one of the leading causes of preventable
death and alcohol-related liver disease (ARLD). ARLD con-
tinues to be an important cause of death in individuals with
alcohol use disorder (AUD).2,3 In Spain, 4.4% of the general
population between the ages of 15 and 64 years consumes
alcohol in excess (ie, hazardous drinking).4
Alcohol-related mortality disproportionately affects
younger individuals; it results in 2.3 million years of potential
life lost, or around 30 years of life lost per alcohol-associated
death.5 The causal association between alcohol intake and
ARLD has been well demonstrated,3,6 but only a small pro-
portion of individuals that drink heavily develop liver cirrhosis.7
AUD confers an elevated risk of premature death, particularly in
young and middle-aged adults.2 Epidemiological and clinical
data have indicated that the prognosis of alcohol dependence is
negatively impacted by medical comorbidity,3,8 but early mar-
kers of poor survival are scarce.
In animal models, systemic inflammation has been linked to
increased intestinal permeability; this finding is paramount in the
development of ARLD.9,10 In humans, the majority of studies on
inflammation and intestinal permeability have analyzed patients
with cirrhosis of the liver,11,12 but little is known about patients
with less advanced liver disease. Also, we lack information about
factors involved in intestinal permeability and systemic inflam-
mation that might correlate to liver disease. Individuals with
AUD at different stages of ARLD and/or medical comorbidity
may represent a keypopulation for studying the interplaybetween
intestinal permeability, immune activation, and inflammation,
mortality, and other disease-specific outcomes.
Proinflammatory cytokines, like C-reactive protein (CRP)
and interleukin (IL)-6 have been associated with all-cause
mortality in some subsets of patients,13,14 including patientstudy from our group found that patients
ce admitted to detoxification had high
fact, 11% of the cohort died after 3 years
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of follow-up, and mortality was highest in those with the
greatest comorbidity (measured with the Cumulative Illness
Rating Scale-Substance Abuse score).8 It is unknown whether
elevated systemic inflammation and elevated intestinal per-
meability might form the link between medical comorbidity
and increased mortality in patients with AUD.
Chronic inflammation and intestinal permeability can be
detected by measuring the levels of several biomarkers and
cytokines.12 However, those tests are associated with issues
regarding cost and standardization, which limit their utility in
daily clinical practice.15 Therefore, there is a need for surrogate
markers of inflammation that might serve as early prognostic
factors of poor outcomes in patients with AUD.
In the present study, we aimed to assess the association
between baseline markers of inflammation (presence of ane-
mia16 and levels of ferritin17 and fibrinogen18) and all-cause
mortality in a cohort of patients with AUD admitted for hospital
detoxification at 2 hospitals in the Barcelona metropolitan area.
PATIENTS AND METHODS
This longitudinal study included a cohort of patients with
alcohol dependence that were admitted for detoxification to
2 hospital units located in metropolitan Barcelona, Spain from
2000 to 2010. One hospital was the Hospital Universitari de
Bellvitge in L’Hospitalet de Llobregat, and the other was the
Hospital Universitari Germans Trias i Pujol in Badalona.
All patients provided written informed consent before
entering the study. The present study was approved by the
Ethics Committee at the Hospital Universitari Germans Trias
i Pujol. Methods used for conducting this study complied with
the ethical standards for medical research and the principles of
good clinical practice in accordance with the World Medical
Association’s Declaration of Helsinki.
At admission, we recorded the sociodemographic charac-
teristics, use of alcohol or other drugs, and routine laboratory
parameters for all patients. The laboratory parameters included,
among others, hemoglobin levels, mean corpuscular volume
(MCV), leukocyte and lymphocyte counts, platelet count, gen-
eral biochemistry parameters from two liver enzyme tests
(aspartate amino-transferase [AST] and alanine amino-transfer-
ase [ALT]), and bilirubin levels. In addition, we analyzed blood
samples to rule out infections from human immunodeficiency
virus (HIV), hepatitis C virus (HCV), and hepatitis B virus
(HBV; tested with HBsAg and HBcAb).
Additional information about the admission protocol can
be found elsewhere.8,19
Independent Variables
Three different surrogate markers of systemic inflam-
mation were chosen, anemia, fibrinogen, and ferritin. The
values were treated as dichotomous; thus, we assigned
thresholds based on normal values of hemoglobin, fibrinogen,
and ferritin to distinguish inflammatory status from normal
status. The thresholds for anemia were based on the World
Health Organization definition of normal levels (hemoglobin
<12 g/dL for women and <13 g/dL for men).20 The thresholds
for high fibrinogen and ferritin levels were >4.5mg/dL and
>200 ng/mL, respectively, based on the upper limits of normal.
Fuster et alOther Covariates
For the purpose of this study, ARLD was diagnosed for
patients that met2 of the following criteria upon admission:3,21
2 | www.md-journal.comAST levels were between 74 and 300 IU/L; the ratio of AST/ALT
was 2; and total bilirubin was >1.2mg/dL
Outcomes During Follow-up
The dates and causes of death were ascertained by review-
ing clinical charts and crosschecking with the mortality register
through December 31, 2010. Causes of death were classified
according to the International Classification of Diseases, ver-
sion 10 (ICD-10).22 We recodified causes of death according to
the ICD-10 codes with an algorithm described elsewhere.23
Statistical Analysis
When patients were admitted more than once during the
studyperiod,we analyzedonly the data from their first admission.
Data from the 2 hospitals were controlled to exclude duplicates.
Descriptive statistics were expressed as the median and
interquartile range (IQR) for quantitative variables and as
absolute frequencies and percentages for qualitative variables.
The main baseline characteristics were stratified according
to the presence of surrogate markers of inflammation to com-
pare groups. Differences among groups were analyzed with the
chi-square test for qualitative variables and with the t student
test for quantitative variables.
Mortality rates were calculated in person-years (p-y).
Mortality ratios were calculated with the reference category
defined as the absence of anemia or normal levels of ferritin
and fibrinogen.
Cox proportional hazards regression models were used to
analyze the predictors of death. The 3 markers were included as
potential predictors of death. Age and sex were among the
predictors of death explored in our adjusted analysis. Also, other
covariates, like viral infections or the presence of ARLD, were
chosen as potential predictors a priori because they had been
associated with mortality in prior studies with the same cohort.23
The proportional hazards assumption was checked for all vari-
ables. The covariates used for multivariate analysis were ident-
ified as statistically significant variables in theunivariate analysis.
In addition, to assess the mortality rates in patients with
anemia, we assigned patients to subgroups based on their MCV;
this approach allowed us to disentangle the impact of normo-
cytic anemia on mortality. For this purpose, MCVs<80 fL were
defined as microcytic anemia; MCVs between 80 and 95 fL
were defined as normocytic anemia; and MCVs >95 fL were
defined as macrocytic anemia.
Statistical tests were 2-sided, and P values <0.05 were
considered statistically significant. Analyses were performed
with SPSS 15.0 (SPSS, Chicago, IL, USA).
RESULTS
The present study included 909 consecutive patients with
alcohol dependence. Table 1 shows the baseline characteristics of
the study population. Patients were predominantlymale (80.3%),
with a median age of 44 years (IQR: 38–50). The median daily
alcohol intake at admissionwas 192 g (IQR: 120–265); 18.3% of
patients had prior injected drug use, 9.4% were on methadone
treatment, and 8.9% reported cocaine use. More than 20% of
patients were infected with HCV, 25.1% had been exposed to
HBV (HBcAb-positive), but only a very small proportion had
active HBV infections (HBsAg-positive); 8.3% were infected
Medicine  Volume 94, Number 10, March 2015with HIV.
Regarding markers of inflammation, 25.9% of patients had
serum fibrinogen levels >4.5mg/dL and almost half the study
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Baseline Characteristics of 909 Patients With AUD
Admitted for Hospital Detoxification in Metropolitan Barce-
lona, Spain 2000–2010
Total (N¼ 909)
Male sex, n (%) 730 (80.3)
Age (years), median (IQR) 44 (38–50)
Alcohol consumption at admission
(g/day), median (IQR) (n¼ 869)
192 (120–265)
Comorbidities
HIV infection, n (%) (n¼ 903) 75 (8.3)
HCV infection, n (%) (n¼ 896) 194 (21.7)
HBsAg, n (%) (n¼ 832) 14 (1.7)
Presence of ARLD, n (%) (n¼ 864) 126 (14.6)
Surrogate markers of inflammation
Hemoglobin (g/dL), median (IQR)
(n¼ 889)
14 (12.9–15.1)
<12 g/dL in females and <13 gr/ dL
in males, n (%)
182 (20.5)
Fibrinogen (mg/dL), median (IQR)
(n¼ 812)
3.6 (2.8–4.5)
>4.5, n (%) 210 (25.9)
Ferritin (ng/mL), median (IQR)
(n¼ 738)
198.4 (105.5–394.4)
>200, n (%) 365 (49.5)
ARLD¼ alcohol-related liver disease, HBsAg¼Hepatitis B surface
Medicine  Volume 94, Number 10, March 2015population had ferritin levels >200 ng/dL. Anemia was present
in 20.5% of patients.
Regarding liver enzyme tests, the median AST and ALT
levels were 42 IU/L (IQR: 24–78) and 36 IU/L (IQR: 22–66),
respectively; the median bilirubin level was 0.7mg/dL (IQR:
0.5–1.1). The median MCV was 98.1 fL (IQR: 94.0–102.9);
the median leukocyte, lymphocyte, and platelet counts
were 6.6 109 cells/L (IQR: 5.3–8.1), 1.9 109 cells/L (IQR:
1.4–2.4), and 195 109 cells/L (IQR: 143–249), respectively.
We also performed a stratified analysis to assess disease
correlates of the 3 surrogate markers of inflammation, as shown
in Table 2. Of note, compared with patients without anemia,
patients with anemia were more likely to be older (46 vs 43
years, P< 0.01), infected with HIV (11.6% vs 7%, P< 0.04),
and exhibit ARLD (29% vs 10.9%, P< 0.01). In addition, those
with anemia had higher ferritin levels, but lower leukocyte
(5.3 109 vs 6.9 109 cells/L, P< 0.01), lymphocyte
(1.5 109 vs 2.0 109 cells/L, P< 0.01), and platelet counts
(164 109 vs 199 109 cells/L, P< 0.01) than those with
normal hemoglobin levels.
Table 2 shows that patients with fibrinogen >4.5mg/dL
were less likely to be infected with HCV (10.6% vs 24%,
P< 0.01), had lower alcohol consumption levels (160 vs
200 g/day, P< 0.01), and were less likely to harbor ARLD
(9.5% vs 15.6%, P¼ 0.03) than those with lower fibrinogen
levels. In addition, patients with high fibrinogen were less likely
than those with low fibrinogen to have a drug use history; for
example, methadone treatment (4% vs 9.7%, P¼ 0.01), prior
injected drug use (9.1% vs 21.6%, P< 0.01), and prior cocaine
antigen, HCV¼ hepatitis C virus, HIV¼ human immunodeficiency
virus, IQR¼ interquartile range.use (3.8% vs 9%,P¼ 0.02). Those with high fibrinogen also had
a higher platelet count (223 109 vs 187 109 cells/L,
P< 0.01) than those with fibrinogen 4.5mg/dL.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.Patients with ferritin levels >200 ng/dL were more often
male (86.6% vs 74.8%, P< 0.01), had a greater daily alcohol
intake at admission (200 vs 175 g, P¼ 0.04), and more fre-
quently exhibited ARLD (21.2% vs 6.8%, P< 0.01) compared
with those with low ferritin. Also, patients with high ferritin
levels had higher MCVs (means 100 vs 95.8 fL, P< 0.01) and
lower platelet counts (172 109 versus 205 109 cells/L,
P< 0.01) than patients with normal ferritin levels.
Outcomes at the End of Follow-up
The median follow-up was 3.8 years (IQR: 1.8–6.5), and
the total follow-up was 3861 p-y. At the end of the study, 118
patients had died (12.9%); the mortality rate was 3.06 100 p-y
(95% confidence interval [CI]: 2.54–3.65).
The mortality rates were 5.65 100 p-y (95% CI: 4.07–
7.63) for participants with anemia, and 2.41 100 p-y (95% CI:
1.89–3.05) for those without anemia; thus, the mortality ratio
was 2.34 (95% CI: 1.59–3.41, P< 0.01). The mortality rates
were 3.70 100 p-y (95% CI: 2.44–5.38) for patients with
fibrinogen levels >4.5mg/dL, and 2.90 100 p-y (95% CI:
2.30–3.61) for those with fibrinogen 4.5mg/dL; thus, the
mortality ratio was 1.27 (95% CI: 0.82–1.96; p¼ 0.27).
Mortality rates were 3.57 100 p-y (95% CI: 2.69–4.66) for
patients with ferritin levels >200 ng/dL, and 2.73 100 p-y
(95% CI: 1.95–3.72) for patients with ferritin levels  200 ng/
dL; thus, the mortality ratio was 1.31 (95% CI: 0.87–1.99;
P¼ 0.20).
The main causes of death in the total study group were
liver-related (37.4%), cancer-related (21.2%), and cardiovas-
cular (13.3%). Of interest, liver-related deaths were not evenly
distributed among groups; they comprised 8.1% of deaths in
those with fibrinogen levels>4.5mg/dL and 46.3% of deaths in
participants with anemia.
Table 3 shows the Cox proportional hazards model results.
In the unadjusted analysis, age, HIV infection, HCV infection,
ARLD, and anemia were associated with mortality. However,
fibrinogen and ferritin levels were not associated with mortality.
In the multivariate analysis, the presence of anemia was associ-
ated with mortality. The hazard ratio (HR) was 1.67 (95% CI:
1.11–2.52, P< 0.01).
Of note, in the fully adjusted model, among the covariates,
age at admission (HR: 1.04; 95% CI: 1.02–1.06; P< 0.01),
HCV infection (HR: 1.89; 95% CI: 1.18–3.04; P< 0.01), and
the presence of ARLD (HR: 1.61; 95%CI: 1.01–2.58;P¼ 0.05)
were also associated with an increased risk of death. In addition,
the association between HIV infection and mortality was bor-
derline significant (HR: 1.79; 95% CI: 0.98–3.28; P¼ 0.06).
Subgroup Analysis of Patients With Anemia
Out of the 182 patients with anemia, 10 (5.5%) had MCVs
<80 fL, 44 (24.2%) had MCVs between 80 and 95 fL, and 128
patients (70.3%) hadMCVs>95 fL, consistent with microcytic,
normocytic, and macrocytic anemia, respectively. At the end of
follow-up, none of the patients in the microcytic anemia group
had died; there were 10 deaths in the normocytic anemia group
(mortality rate: 5.8 100 p-y [95% CI: 2.95–10.34]), and 32
deaths in the macrocytic anemia group (mortality rate:
6.05 100 p-y [95% CI: 4.21–8.44]).
When those without anemia and normal MCVs were
used as the reference group, the mortality ratios of patients
Inflammation and Mortality in Alcohol Dependencewith normocytic and macrocytic anemia were 3.25 (95% CI:
1.41–7.26; P< 0.01) and 3.39 (95% CI: 1.86–6.43; P< 0.01),
respectively (Figure 1). Figure 1 also shows that patients
www.md-journal.com | 3
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TABLE 3. Univariate andMultivariate Cox RegressionModels for the Association Between Inflammatory Markers andMortality in
909 Patients With AUD Admitted for Detoxification in Metropolitan Barcelona, Spain 2000–2010
Univariate Analysis Multivariate Analysis
Variable Hazard Ratio (95% CI) P Hazard Ratio (95% CI) P
Male sex 0.70 (0.43–1.15) 0.16
Age at admission 1.03 (1.01–1.05) <0.01 1.04 (1.02–1.06) <0.01
HIV infection 2.56 (1.61–4.07) <0.01 1.79 (0.98–3.28) 0.06
HCV infection 2.20 (1.51–3.21) <0.01 1.89 (1.18–3.04) <0.01
HBsAg-positive 0.86 (0.29–4.73) 0.83
Presence of ARLD 1.96 (1.25–3.06) <0.01 1.61 (1.01–2.58) 0.05
Anemia 2.33 (1.59–3.41) <0.01 1.67 (1.11–2.52) <0.01
Fibrinogen >4.5mg/dL 1.27 (0.82–1.97) 0.28
Ferritin >200 ng/mL 1.32 (0.87–2.00) 0.19
BsA
Medicine  Volume 94, Number 10, March 2015 Inflammation and Mortality in Alcohol Dependencewithout anemia and MCVs >95 fL had a mortality rate of
2.76 100 p-y (95% CI: 2.01–3.44). When this group was
used as the reference group, the mortality ratio of those with
macrocytic anemia was 2.28 (95% CI: 1.46–3.52; P< 0.01).
DISCUSSION
In this cohort study of patients with alcohol dependence
admitted for detoxification, the presence of anemia was associ-
ated with an elevated risk of mortality. However, we were
unable to find an association between fibrinogen or ferritin
levels and mid-term mortality.
The association between anemia and mortality remained
ARLD¼ alcohol-related liver disease, AUD¼ alcohol use disorder, H
immunodeficiency virus.significant in the model after adjusting for other markers of poor
clinical outcomes, such as age, HIV infection, HCV infection,
and the presence of ARLD. Of interest, HCV infection was also
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HR = 3.4 (95% CI:1.9–6.4) 
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with normocytosis
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(n = 44)
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FIGURE 1. Unadjusted mortality rates and hazard ratios (HRs) of
death according to anemia status in patients with AUD admitted
for detoxification treatment.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.associated with overall mortality in the adjusted Cox regression
model; this finding was consistent with prior findings in the
same cohort.23 Among the studied covariates, other predictors
of death were age and the presence of ARLD, and there was also
a borderline-significant association between HIV infection and
all-cause mortality.
Anemia has been regarded to indicate increased risk of
mortality in different settings, including heart failure,24 acute
ischemic stroke,25 bacteremia,26 myocardial infarction at
advanced age,27 surgery,28 and severe alcoholic hepatitis.29
We are not aware of any previous studies that have analyzed
the prognostic value of anemia in patients with alcohol depen-
dence admitted for detoxification.
In addition to its value as a surrogate marker of chronic
inflammation, anemia may also arise from multiple factors in
patients with AUD.16,30 The differential diagnosis of anemia in
patients with alcohol dependence includes hemolytic anemia,
megaloblastic anemia due to folate and/or vitamin B12 deficits,
or syderoblastic anemia.31 In our study group, a significant
number of patients with anemia had normal MCV values.
Normocytic anemia is most commonly associated with inflam-
mation and chronic diseases.16 In the subgroup analysis that we
performed, after excluding patients with abnormalMCV values,
those with normocytic anemia had increased risk of death, with
a mortality ratio of 3.25 (95% CI: 1.41–7.26).
It is important to note that patients with macrocytic anemia
also had a very high mortality rate, and when compared with
patients with macrocytosis, but without anemia, they had a
significantly higher risk of death, with a mortality ratio of 3.39
(95% CI: 1.86–6.43). Therefore, anemia had a higher impact on
mortality than alcohol-driven bone marrow toxicity. Given that
an etiologic study of anemia in those with AUD is not always
feasible, there may be other markers of inflammation that could
more effectively stratify patients with alcohol dependence to
analyze risk of death. Those markers might include IL-6 and
CRP,15,32 which were previously associated with inflammation
and mortality in some subsets of patients. Also, sCD14, a
marker of intestinal permeability,33 has been shown to be
associated with mortality in different populations.33–34
Our finding that high fibrinogen levels were not associated
g¼ hepatitis B surface antigen, HCV¼ hepatitis C virus, HIV¼ humanwith mortality in this cohort merits some discussion. Other
researchers have proposed that low fibrinogen levels in indi-
viduals with moderate alcohol intake were associated with
www.md-journal.com | 5
reduced cardiovascular mortality.35,36 Interestingly, in our
study population, among the patients with AUD, those with
the highest fibrinogen levels had the lowest alcohol consump-
tion levels at admission. In addition, compared with those with
low fibrinogen levels, those with higher fibrinogen levels had a
lower prevalence of other markers of poor prognosis, like HCV
infection, or presence of ARLD. Therefore, it is possible that the
potential benefit that moderate alcohol intake and low fibrino-
gen levels have on some cardiovascular outcomes may be lost in
individuals who consume unhealthy amounts of alcohol or have
alcohol dependence.
Ferritin acts as an acute-phase reactant; therefore, ferritin
levels might reflect the levels of iron, which is a cofactor in the
progression of liver disease in individuals with AUD.37,38 In our
study, the group of patients with higher ferritin levels tended to
be male and they tended to drink more heavily (at admission)
than those with lower ferritin levels. Nevertheless, we found
that ferritin levels >200 ng/dL had no impact on mid-term
mortality. Of interest, in our cohort, male sex and baseline
alcohol intake were not associated with an increased risk of
death. A potential explanation for our finding that ferritin levels
could not discriminate patients at high risk of death was the high
prevalence of hyperferritinemia. Nearly half of our population
had ferritin levels>200 ng/mL, and two-thirds of the population
had ferritin levels >100 ng/mL.
Of note, in the 3 different groups of fibrinogen, ferritin, or
hemoglobin levels, there was an uneven distribution of ARLD.
However, ARLD did not have an impact on mortality, except in
the group with anemia. In the fully adjusted Cox regression,
both the presence of ARLD and anemia were independently
associated with mortality. Therefore, our definition of ARLD
might be used as a tool for detecting patients with alcohol
dependence that are at increased risk of death.
Also, among the groups of patients with different markers
of inflammation, there was an uneven distribution of liver-
related deaths. Liver-related deaths accounted for almost half
the deaths in the group of patients with anemia.
In our cohort of patients with alcohol dependence, cardi-
ovascular death was the third cause of death, after liver-related
and cancer-related deaths. It was surprising that a group of
patients in their mid 40s had such high mid-term cardiovascular
mortality. This finding emphasized the importance of inflam-
mation in patients with alcohol dependence.
The present study had several limitations. First, we only
conducted one determination of surrogate markers of inflam-
mation at admission. Indeed, the evolution of those markers
could have had a greater impact on mortality than a single
determination. Also, we were not able to adjust the analysis for
the presence of alcohol abstinence over time, after hospital
discharge; this factor is a known marker of prognosis.3 In
addition, as we previously mentioned, we did not have sufficient
laboratory information for a full characterization of the anemia
in patients with low hemoglobin levels. Finally, we could not
adjust our analysis for other markers of poor outcomes in
middle-aged adults, such as smoking or the presence
of hypertension.
The present study had important strengths. We recruited a
large study population with a relatively long follow-up, the
mortality data included causes of death, and we had a wide
range of patient-level data.
In summary, in this study of surrogate markers of inflam-
Fuster et almation in a cohort of patients with alcohol dependence, we
showed that the presence of anemia was associated with all-
cause mortality. Future research should focus on exploring other
6 | www.md-journal.commarkers of inflammation and intestinal permeability that might
be used for the prognosis of patients with alcohol dependence.
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